PROMISE trial reveals smokers' distinct coronary CTA plaque features

Kate Madden Yee, Senior Editor, AuntMinnie.com. Headshot

Monday, December 1 | 8:20 a.m.-8:30 a.m. | M1-SSCA03-3 | Room S503

Researchers have found that CT angiography (CTA)-derived plaque characterization could help assess adverse cardiovascular event risk in individuals with a smoking history.

Presenter Nora Kerkovits, MD, of Semmelweis University in Hungary, and colleagues used data from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial to investigate any associations between smoking, CT-derived plaque characteristics, and adverse cardiovascular events.

Their research included 4,402 patients with stable chest pain, suspected coronary artery disease, and available CT data. They tracked the following measures: coronary artery calcium (CAC); high-risk plaque features; obstructive disease; Leaman score (used to quantify the total burden of plaque buildup in the coronary arteries); and total, calcified, noncalcified, and low-density plaque volume. The group also assessed any associations between ever-smoking and plaque measures, adjusting for age, sex, body mass index, hypertension, dyslipidemia, and a family history of early coronary artery disease.

The team's main finding was that, in stable chest pain patients, ever-smoking was independently linked to distinct coronary plaque phenotypes -- such as high-risk plaque features and high plaque volume -- and increased cardiovascular event risk.

Stop by this session to learn more.

Page 1 of 2
Next Page